(Q43284332)

18 November 2017

0 references

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? (English)

1 reference

18 November 2017

main subject

ascending cholangitis

0 references

sclerosing cholangitis

1 reference

primary sclerosing cholangitis

inferred from title

1 reference

Roger W Chapman

1

1 reference

18 November 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

18 November 2017

1 reference

18 November 2017

volume

50

1 reference

18 November 2017

issue

3

1 reference

18 November 2017

page(s)

671-673

1 reference

An update on primary sclerosing cholangitis.

18 November 2017

cites work

1 reference

Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited

21 January 2018

1 reference

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

21 January 2018

1 reference

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

21 January 2018

1 reference

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

21 January 2018

1 reference

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

21 January 2018

1 reference

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective

21 January 2018

1 reference

High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis

21 January 2018

1 reference

Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles

21 January 2018

1 reference

Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis.

21 January 2018

1 reference

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice

21 January 2018

1 reference

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis

21 January 2018

1 reference

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

21 January 2018

1 reference

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.

21 January 2018

1 reference

Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy

21 January 2018

1 reference

Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey

21 January 2018

1 reference

Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation

21 January 2018

1 reference

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

7 January 2021

Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.23174

1 reference

18 November 2017

1 reference